查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1396817

全球乾眼症治療市場：依藥物、劑型和配銷通路：機會分析與產業預測（2023-2032）

Dry Eye Syndrome Treatment Market By Drug, By Dosage form, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 235 Pages | 商品交期: 2-3個工作天內

價格

預計2022年全球乾眼症治療市場規模將達47.25億美元，2023年至2032年年複合成長率為7.1%，2032年將達93.165億美元。

乾眼症是一種常見疾病，當患者的眼淚無法為眼睛提供足夠的潤滑時就會發生。乾眼症（DED），也稱為乾眼症（DES）、色盲角結膜炎（KCS）和色盲角膜炎，是由於淚膜穩態喪失而導致的眼表多因子疾病。

老年人口的增加，乾眼症患者病率的迅速增加以及對有效治療的需求不斷增加推動了乾眼症治療市場的成長。在老年人中，淚腺產生眼淚的效率降低。因此，淚液分泌不足會導致乾眼症。例如，根據聯合健康基金會美國健康排名發布的報告，預計2021年美國將有超過5400萬65歲及以上的成年人居住，約占美國人口的16.5%。相等的。

此外，領先的醫療技術公司越來越注重收購提供乾眼症治療解決方案的公司，預計這將大大促進市場成長。全球乾眼症治療藥物市場的主要企業投資於產品發布、收購和研發，以促進乾眼症治療藥物的進步，以加強其市場地位並保持競爭。已採取多種策略，例如:例如，2023年1月，全球醫療保健公司Viatris Inc.宣布完全收購Oyster Point Pharma和Famy Life Sciences，創建新的Viatris眼部護理部門。

此外，乾眼症（DED）盛行率的驚人增加、乾眼症治療藥物的技術進步以及隱形眼鏡的長期使用是推動市場成長的關鍵因素。此外，長時間使用螢幕和電腦工作是導致乾眼症（DES）盛行率增加的重要因素。然而，嚴格的藥物核准監管程序和缺乏熟練的眼科醫生可能會限制市場成長。相反，乾眼症治療在老年人群中的廣泛應用以及最近推出的藥物預計將在不久的將來為市場成長提供利潤豐厚的機會。此外，乾眼症治療藥物領域的廣泛研發活動以及醫療基礎設施的顯著改善預計將為預測期內的市場擴張開闢新途徑。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 乾眼症增加
      • 增加螢幕時間和隱形眼鏡的使用率
      • 老年人口增加
    • 抑制因素
      • 對乾眼症缺乏認知
    • 機會
      • 最新的產品核可和開拓的巨大市場潛力

第4章 乾眼症治療藥物市場：依藥物分類

  • 概述
  • 潤滑劑
  • 乾眼症治療
  • 其他

第5章 乾眼症治療藥物市場：按劑型

  • 概述
  • 眼藥水
  • 軟膏
  • 其他

第6章 乾眼症治療藥物市場：依配銷通路

  • 概述
  • 醫院藥房
  • 零售藥房
  • 線上提供者

第7章 乾眼症治療藥物市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 主要企業定位（2022年）

第9章 公司簡介

  • AbbVie Inc.
  • Viatris Inc.
  • Novartis AG
  • Bausch Health Companies Inc
  • Sun Pharmaceutical Industries Ltd.
  • Novaliq
  • Santen Pharmaceutical Co., Ltd.
  • AFT Pharmaceuticals Limited
  • Alcon
  • Johnson & Johnson（J&J）
Product Code: A02472

The Dry Eye Syndrome Treatment Market was valued for $4,725.00 million in 2022 and is estimated to reach $9,316.50 million by 2032, exhibiting a CAGR of 7.1% from 2023 to 2032.

Dry eye disease is a common condition that occurs when a patient's tears are unable to provide adequate lubrication for their eyes. Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film.

The growth of the dry eye syndrome treatment market is driven by rise in geriatric population, surge in prevalence of dry eye diseases, and increase in demand for effective treatment. In the geriatric people, there is decrease in efficiency of lacrimal glands to produce tears. Thus, lack of tears production leads to dry eye condition in geriatric people. For instance, according to the report published by the America's Health Ranking by United Health Foundation, in 2021, it has been estimated that more than 54 million adults aged 65 and older live in the U.S., which is about 16.5% of the nation's population.

Moreover, large medical technology firms have increasingly focused on acquiring companies that provide solutions for dry eye syndrome treatments, which is expected to notably contribute toward the market growth. Prominent players in the global dry eye syndrome treatment market have adopted various strategies such as product launches, acquisitions, and investments in R&D for advancement in dry eye syndrome treatments to strengthen their position in the market and sustain the competitive environment. For instance, in January 2023, Viatris Inc., a global healthcare company, announced its complete acquisition of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division.

Moreover, alarming increase in prevalence of dry eye diseases (DED), technological advancements in dry eye syndrome treatment, and long-term use of contact lens are some of the key factors that drive the growth of the market. Furthermore, extensive screen time and computer-based work notably contribute toward the growth in prevalence of dry eye syndrome (DES). However, stringent regulatory process for drug approval and dearth of skilled ophthalmologists may restrain the market growth. Conversely, increased application of dry eye syndrome treatment among the geriatric population and recent drug launched in market is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R&D activities in the field of dry eye syndrome treatment along with significant improvement in medical infrastructure are anticipated to open new avenues for the expansion of the market during the forecast period.

The dry eye syndrome treatment market is segmented into drug, dosage form, distribution channel, and region. On the basis of drug, the market is classified into lubricant, dry eye syndrome drugs and others. On the basis of dosage form, the market is categorized into eye drops, ointments, and others. On the basis of distribution channel, it is classified into hospital pharmacies, retail pharmacies and online providers. On the basis of region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include Abbvie, Viatris, Novartis AG, Bausch & Lomb Incorporated, Sun Pharma, Novaliq, Santen Pharmaceutical Co., AFT Pharmaceuticals, Alcon and Johnson & Johnson.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dry eye syndrome treatment market analysis from 2022 to 2032 to identify the prevailing dry eye syndrome treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dry eye syndrome treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dry eye syndrome treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Drug

  • Lubricant
  • Dry eye syndrome drugs
  • Others

By Dosage form

  • Eye drops
  • Ointments
  • Other

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Viatris Inc.
    • Novartis AG
    • Bausch Health Companies Inc
    • Novaliq
    • AFT Pharmaceuticals Limited
    • Alcon
    • Johnson & Johnson (J&J)
    • Santen Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of dry eye syndrome
      • 3.4.1.2. Increase in screen time and rise in adoption of contact lens
      • 3.4.1.3. Upsurge in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness about dry eye syndrome
    • 3.4.3. Opportunities
      • 3.4.3.1. Latest product approvals and high untapped market potential

CHAPTER 4: DRY EYE SYNDROME TREATMENT MARKET, BY DRUG

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Lubricant
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Dry eye syndrome drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Eye drops
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Ointments
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Other
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: DRY EYE SYNDROME TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Drug
    • 7.2.3. Market size and forecast, by Dosage form
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Drug
      • 7.2.5.1.2. Market size and forecast, by Dosage form
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Drug
      • 7.2.5.2.2. Market size and forecast, by Dosage form
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Drug
      • 7.2.5.3.2. Market size and forecast, by Dosage form
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Drug
    • 7.3.3. Market size and forecast, by Dosage form
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Drug
      • 7.3.5.1.2. Market size and forecast, by Dosage form
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Drug
      • 7.3.5.2.2. Market size and forecast, by Dosage form
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Drug
      • 7.3.5.3.2. Market size and forecast, by Dosage form
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Drug
      • 7.3.5.4.2. Market size and forecast, by Dosage form
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Drug
      • 7.3.5.5.2. Market size and forecast, by Dosage form
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Drug
      • 7.3.5.6.2. Market size and forecast, by Dosage form
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Drug
    • 7.4.3. Market size and forecast, by Dosage form
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Market size and forecast, by Drug
      • 7.4.5.1.2. Market size and forecast, by Dosage form
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Market size and forecast, by Drug
      • 7.4.5.2.2. Market size and forecast, by Dosage form
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Drug
      • 7.4.5.3.2. Market size and forecast, by Dosage form
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Drug
      • 7.4.5.4.2. Market size and forecast, by Dosage form
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Drug
      • 7.4.5.5.2. Market size and forecast, by Dosage form
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Drug
      • 7.4.5.6.2. Market size and forecast, by Dosage form
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Drug
    • 7.5.3. Market size and forecast, by Dosage form
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Drug
      • 7.5.5.1.2. Market size and forecast, by Dosage form
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Drug
      • 7.5.5.2.2. Market size and forecast, by Dosage form
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Drug
      • 7.5.5.3.2. Market size and forecast, by Dosage form
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Drug
      • 7.5.5.4.2. Market size and forecast, by Dosage form
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Viatris Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Novartis AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Bausch Health Companies Inc
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Sun Pharmaceutical Industries Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Novaliq
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Key strategic moves and developments
  • 9.7. Santen Pharmaceutical Co., Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. AFT Pharmaceuticals Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Alcon
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Johnson & Johnson (J&J)
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 02. DRY EYE SYNDROME TREATMENT MARKET FOR LUBRICANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. DRY EYE SYNDROME TREATMENT MARKET FOR DRY EYE SYNDROME DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. DRY EYE SYNDROME TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 06. DRY EYE SYNDROME TREATMENT MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. DRY EYE SYNDROME TREATMENT MARKET FOR OINTMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. DRY EYE SYNDROME TREATMENT MARKET FOR OTHER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. DRY EYE SYNDROME TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. DRY EYE SYNDROME TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. DRY EYE SYNDROME TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. DRY EYE SYNDROME TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 19. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 20. U.S. DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 22. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 23. CANADA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 38. UK DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 39. UK DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 41. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 42. ITALY DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 54. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 55. CHINA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 60. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 61. INDIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC.: KEY STRATERGIES
  • TABLE 92. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 93. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 94. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 95. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 96. VIATRIS INC.: KEY STRATERGIES
  • TABLE 97. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 101. BAUSCH HEALTH COMPANIES INC: KEY EXECUTIVES
  • TABLE 102. BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
  • TABLE 103. BAUSCH HEALTH COMPANIES INC: PRODUCT SEGMENTS
  • TABLE 104. BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
  • TABLE 105. BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
  • TABLE 106. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 111. NOVALIQ: KEY EXECUTIVES
  • TABLE 112. NOVALIQ: COMPANY SNAPSHOT
  • TABLE 113. NOVALIQ: PRODUCT SEGMENTS
  • TABLE 114. NOVALIQ: PRODUCT PORTFOLIO
  • TABLE 115. NOVALIQ: KEY STRATERGIES
  • TABLE 116. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 117. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 118. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 119. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 120. SANTEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
  • TABLE 121. AFT PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 122. AFT PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 123. AFT PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 124. AFT PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. ALCON: KEY EXECUTIVES
  • TABLE 126. ALCON: COMPANY SNAPSHOT
  • TABLE 127. ALCON: PRODUCT SEGMENTS
  • TABLE 128. ALCON: PRODUCT PORTFOLIO
  • TABLE 129. JOHNSON & JOHNSON (J&J): KEY EXECUTIVES
  • TABLE 130. JOHNSON & JOHNSON (J&J): COMPANY SNAPSHOT
  • TABLE 131. JOHNSON & JOHNSON (J&J): PRODUCT SEGMENTS
  • TABLE 132. JOHNSON & JOHNSON (J&J): PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. DRY EYE SYNDROME TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF DRY EYE SYNDROME TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN DRY EYE SYNDROME TREATMENT MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL DRY EYE SYNDROME TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. DRY EYE SYNDROME TREATMENT MARKET, BY DRUG, 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR LUBRICANT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR DRY EYE SYNDROME DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR EYE DROPS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR OINTMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR OTHER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DRY EYE SYNDROME TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. DRY EYE SYNDROME TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 23. U.S. DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA DRY EYE SYNDROME TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: DRY EYE SYNDROME TREATMENT MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. BAUSCH HEALTH COMPANIES INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. BAUSCH HEALTH COMPANIES INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. SANTEN PHARMACEUTICAL CO., LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. AFT PHARMACEUTICALS LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. AFT PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. ALCON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. ALCON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. ALCON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. JOHNSON & JOHNSON (J&J): RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2021 ($BILLION)
  • FIGURE 68. JOHNSON & JOHNSON (J&J): NET REVENUE, 2020-2022 ($BILLION)
  • FIGURE 69. JOHNSON & JOHNSON (J&J): REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 70. JOHNSON & JOHNSON (J&J): REVENUE SHARE BY SEGMENT, 2022 (%)